Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

161. Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial. Full Text available with Trip Pro

Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial. Objective. To evaluate the efficacy and safety of Rhubarb supplementation in patients of chronic kidney disease. Material and Methods. This study was a prospective comparative study conducted in patients of chronic kidney disease (stages 3 & 4) attending Renal Clinic of Department of Medicine, JN Medical College & Hospital, AMU, Aligarh. Patients were randomly divided into two (...) management in stage 3 and stage 4 patients of chronic kidney disease.

2015 International journal of chronic diseases Controlled trial quality: uncertain

162. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. (Abstract)

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin-free regimen (...) in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease.In this phase 3 randomised study of safety and observational study of efficacy, patients with HCV genotype 1 infection and chronic kidney disease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to receive grazoprevir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment group) or placebo (deferred treatment group) once daily for 12 weeks. Randomisation was done

2015 Lancet Controlled trial quality: predicted high

163. A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown

A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown UTCAT2938, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown Clinical Question In patients with chronic kidney disease, does periodontal treatment improve (...) kidney function (estimated glomerular filtration rate (eGFR))? Clinical Bottom Line Periodontal disease and chronic kidney disease share similar risk factors (smoking, impaired wound healing, diabetes mellitus, malnutrition, and poor oral hygiene) and a positive association between the two diseases has been shown. Intervention studies offer limited and inconsistent evidence for improvement following periodontal treatment in patients with CKD and periodontitis. No adverse outcomes were seen

2015 UTHSCSA Dental School CAT Library

164. Guidelines for the Management of Chronic Kidney Disease (CKD)

with a hospital referral 21 Patient involvement in CKD 21 Appendices Appendix 1 - Where can I get more information? 22 Appendix 2 - Contact Details 23 Appendix 3 - Management of chronic kidney disease: summary table 24 Appendix 4 - Abbreviations 25 Appendix 5 - Membership of GDG 26 3 Introduction Chronic kidney disease (CKD) is common, usually unrecognised and often exists in association with other conditions such as diabetes and cardiovascular disease. CKD is a general term covering a number of primary (...) risk of cardiovascular events, acute kidney injury, falls, frailty and mortality. Table 1: Prevalence of Chronic Kidney Disease Stage Description eGFR (mL/min/1.73m 2 ) Population Prevalence 1 CKD with normal GFR + other kidney damage >90 3.3% 2 Mild CKD and other kidney damage 60-89 3.0% 3a 3b Mild to Moderate CKD Moderate to Severe CKD 45-59 30-44 4.3% 4 Severe CKD 15-29 0.2% 5 Established renal failure 30mg/mmol (macro-albuminuria often dipstick proteinuria) ? GFR in healthy young adults

2015 Regulation and Quality Improvement Authority

165. Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions Full Text available with Trip Pro

equation to estimate GFR is superior for predicting adverse outcomes after PCI and to examine how equation selection would impact drug-dosing recommendations.Estimated GFR (eGFR) was calculated with the Cockcroft-Gault, Modification of Diet in Renal Disease Study (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations for 128,805 patients undergoing PCI in the state of Michigan. Agreement between patient pre-PCI eGFR estimates and resultant CKD stage classifications (...) Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions Multiple equations exist to estimate glomerular filtration rate (GFR); however, there is no consensus on which is superior for risk classification in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI).The goals of this study were to identify which

2015 EvidenceUpdates

166. Chronic kidney disease. Full Text available with Trip Pro

Chronic kidney disease. This issue provides a clinical overview of chronic kidney disease, focusing on prevention, diagnosis, treatment, and patient information. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration

2015 Annals of Internal Medicine

167. Erythropoiesis Stimulating Agents in Chronic Kidney Disease

. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Erythropoiesis Stimulating Agents in Chronic Kidney Disease (...) of vascular access thrombosis and stroke. No impacts of higher Hb targets were observed on end-stage renal disease or all-cause mortality. 2 The identified randomized controlled trial 3 examined the effects of maintaining high Hb on renal function in patients with CKD who were not on dialysis. Patients were randomized to either a Erythropoiesis Stimulating Agents in Chronic Kidney Disease 3 high Hb group (Hb equal to 11.0 g/dL through 13.0 g/dL) receiving darbepoetin alfa or a low Hb group (Hb equal

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

168. Dialysis in Stage 5 Chronic Kidney Disease

, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Dialysis in Stage 5 Chronic Kidney Disease: Clinical Effectiveness and Guidelines DATE (...) estimated GFRs was statistically significantly associated with increased risk of mortality; however, significant study heterogeneity was also noted. Dialysis in Stage 5 Chronic Kidney Disease 3 REFERENCES SUMMARIZED Health Technology Assessments No literature identified Systematic Reviews and Meta-analyses 1. O'Connor NR, Kumar P. Conservative management of end-stage renal disease without dialysis: a systematic review. J Palliat Med [Internet]. 2012 Feb [cited 2015 Mar 13];15(2):228-35. Available from

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

169. Non-Steroidal Anti-Inflammatory Drugs in Patients with Hypertension, Chronic Kidney Disease, or Heart Failure

Non-Steroidal Anti-Inflammatory Drugs in Patients with Hypertension, Chronic Kidney Disease, or Heart Failure Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time (...) -Inflammatory Drugs in Patients with Hypertension, Chronic Kidney Disease, or Heart Failure: Benefits, Harms, and Guidelines DATE: 10 March 2015 RESEARCH QUESTIONS 1. What are the clinical benefits and harms of using non-steroidal anti-inflammatory drugs (NSAIDS) in patients with hypertension, chronic kidney disease, or heart failure? 2. What are the evidence-based guidelines for using NSAIDS in patients with hypertension, chronic kidney disease, or heart failure? KEY FINDINGS One systematic review, one

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

170. Cohort study: Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease Full Text available with Trip Pro

Cohort study: Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) disease Article Text Prognosis Cohort study Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease Nisha Bansal Statistics from Altmetric.com Commentary on : Kovesdy CP , Lu JL , Molnar MZ , et al . Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease . Context Hypertension is a major cause of mortality. Previous studies have identified a J-shaped association between

2015 Evidence-Based Medicine

171. Qualitative?other: People with coexisting diabetes, chronic kidney disease and hypertension report the psychosocial effects of being prescribed multiple medications Full Text available with Trip Pro

Qualitative?other: People with coexisting diabetes, chronic kidney disease and hypertension report the psychosocial effects of being prescribed multiple medications People with coexisting diabetes, chronic kidney disease and hypertension report the psychosocial effects of being prescribed multiple medications | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn (...) more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here People with coexisting diabetes, chronic kidney disease and hypertension report

2015 Evidence-Based Nursing

172. Chronic kidney disease: managing anaemia

illness? Wh Why this is important y this is important Chronic kidney disease is a risk factor for mortality in patients who develop acute illness. Acute illness in CKD patients is associated with development, or worsening, of anaemia. The anaemia of end-stage renal disease is managed primarily with ESAs and intravenous iron. When CKD patients develop acute illness, their anaemia becomes difficult to control. Acute inflammatory response usually renders patients hyporesponsive to treatments for anaemia (...) renal replacement therapy and prolonged hospital stay. 2.2 Treatment of ESA resistance In people with chronic ESA-resistant anaemia of CKD, what is the clinical and cost effectiveness of treating with high-dose ESA compared with blood transfusion? Chronic kidney disease: managing anaemia (NG8) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 27 of 45Wh Why this is important y this is important People with ESA

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines

173. Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide

Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide Key points from the evidence | Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide | Advice | NICE Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide Evidence summary [ESNM51] Published date: January 2015 Share Save Advice Key points from the evidence Key points from the evidence The content of this evidence summary (...) was up-to-date in January 2015 . See (SPCs), (BNF) or the or websites for up-to-date information. Summary Sucroferric oxyhydroxide (Velphoro) is an iron‑based phosphate binder. In 1 open‑label, randomised controlled trial (RCT), sucroferric oxyhydroxide at a mean dose of 1500 mg iron (3 tablets) per day was non‑inferior to sevelamer carbonate at a mean dose of 6.4 g (8 tablets) per day for lowering phosphate levels in adults with chronic kidney disease (CKD) who were on haemodialysis or peritoneal

2015 National Institute for Health and Clinical Excellence - Advice

174. Autosomal Dominant Polycystic Kidney Disease - Management of Chronic Pain

-stage kidney disease may be suitable for laparoscopic nephrectomy. IMPLEMENTATION AND AUDIT Assessment of chronic renal pain in patients with ADPKD attending renal clinics. A quality-of-life survey asking patients with ADPKD about pain control. Use of magnetic resonance imaging to determine whether pain is due to cyst bleeding, infection or enlargement, or to mechanical back pain. BACKGROUND Pain is very common in ADPKD, occurring in up to 60% of patients at some time. 2,3 Renal pain is found (...) group. WHAT DO THE OTHER GUIDELINES SAY? Kidney Disease Outcomes Quality Initiative: No recommendation. UK Renal Association: No recommendation. CanadianSocietyofNephrology:Norecommendation. European Best Practice Guidelines: No recommen- dation. International Guidelines: No recommendation Spanish Guidelines 28 : The cause of chronic pain should be evaluated and corrected if possible. a) Mechanicalbackpainorpainduetorenalenlarge- ment should be managed symptomatically (D). b) Narcotic analgesics

2015 KHA-CARI Guidelines

175. Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome Full Text available with Trip Pro

not reported in this analysis ACS indicates acute coronary syndrome; ACSIS, Acute Coronary Syndromes Israeli Survey; CI, confidence interval; CKD, chronic kidney disease; CrCl, creatinine clearance; CRI, chronic renal insufficiency; ESRD, end-stage renal disease; GFR, glomerular filtration rate; GRACE, Global Registry of Acute Coronary Events; HR, hazard ratio; ICH, intracranial hemorrhage; ICONS, Improved Cardiac Outcomes in Nova Scotia; LBBB, left bundle branch block; OR, odds ratio; PCI, percutaneous (...) rate formula for classification of chronic kidney dis- ease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008;51:991–996. doi: 10.1016/j.jacc.2007.11.045. 24. Wargo KA, Eiland EH 3rd, Hamm W, English TM, Phillippe HM. Comparison of the modification of diet in renal disease and Cockcroft- Gault equations for antimicrobial dosage adjustments. Ann Pharmacother. 2006;40:1248–1253. doi: 10.1345/aph.1G635. 25. Golik MV, Lawrence KR. Comparison of dosing

2015 American Heart Association

176. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min) Full Text available with Trip Pro

, Issue suppl_2, May 2015, Pages ii1–ii142, Download citation file: © 2019 Oxford University Press Navbar Search Filter Mobile Microsite Search Term Close search filter search input 1. ABBREVIATIONS AND ACRONYMS CKD Chronic kidney disease ACE-I ACE inhibitor ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP European Renal Best Practice MD Mean difference OR Odds ratio RR Relative risk 95% CI 95% Confidence interval CKD Chronic kidney disease ACE-I ACE inhibitor (...) ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP European Renal Best Practice MD Mean difference OR Odds ratio RR Relative risk 95% CI 95% Confidence interval 2. FOREWORD Diabetes mellitus is becoming increasingly prevalent and is considered a rapidly growing concern for healthcare systems. Besides the cardiovascular complications, diabetes mellitus is associated with chronic kidney disease (CKD). CKD in patients with diabetes can be caused by true diabetic

2015 European Renal Best Practice

177. Allopurinol for the treatment of chronic kidney disease: a systematic review

Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinolforthetreatmentofchronic kidneydisease:asystematicreview Nigel Fleeman, 1* Gerlinde Pilkington, 1 Yenal Dundar, 1 Kerry Dwan, 1 Angela Boland, 1 Rumona Dickson, 1 Hameed Anijeet, 2 Tom Kennedy 2 and Jason Pyatt 2 1 Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK 2 Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK *Corresponding author Declared (...) competing interests of authors: none Published June 2014 DOI: 10.3310/hta18400 Scientific summary AllopurinolforthetreatmentofCKD Health Technology Assessment 2014; Vol. 18: No. 40 DOI: 10.3310/hta18400 NIHR Journals Library www.journalslibrary.nihr.ac.ukScientificsummary Background The term chronic kidney disease (CKD) is used to describe abnormal kidney function (or structure) and is defined according to the presence or absence of kidney damage and level of kidney function. Traditionally serum

2014 NIHR HTA programme

178. Allopurinol for the treatment of chronic kidney disease: a systematic review

a trial with a larger number of people with chronic kidney disease. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Allopurinols; Renal Insufficiency, Chronic Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber (...) Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinol for the treatment of chronic kidney disease: a systematic review Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been

2014 Health Technology Assessment (HTA) Database.

179. Point-of-Care creatinine testing for the detection and monitoring of chronic kidney disease

of Chronic Kidney Disease Horizon Scan Report 0038 March 2014 Horizon Scan Report 0035 February 2014 d) Detection of acute on chronic renal failure and acute kidney injury (AKI) Existing Technology: Blood samples sent from GP for analysis in local hospital laboratory. Results subsequently sent back to general practice typically within 24 hours. Depending on significance of result, this may or may not be communicated to the patient by letter, telephone or in person. Benefits of POC creatinine testing (...) /nicemedia/live/12069/42117/42117.pdf NICE clinical guideline 73. 6. Mathew TH, Corso O, Ludlow M, Boyle A, Cass A, Chadban SJ, Joyner B, Shephard M, Usherwood T. Screening for chronic kidney disease in Australia: a pilot study in the community and workplace. Kidney International – Supplement. 2010; (116): S9-16. 7. Morita S, Suzuki K, Masukawa A, Ueno E. Assessing renal function with a rapid, handy, point-of-care whole blood creatinine meter before using contrast materials. Japanese Journal of Radiology

2014 Publication 4878904

180. Chronic kidney disease in adults: assessment and management

-and- conditions#notice-of-rights). Page 6 of 60* Relative to young adult level ** Including nephrotic syndrome (ACR usually >220 mg/mmol) Abbreviations: ACR, albumin:creatinine ratio; CKD, chronic kidney disease Reprinted with permission from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International (Suppl. 3): 1–150 Late presentation of people with kidney failure increases (...) hypertension acute kidney injury (see recommendation 1.3.9) Chronic kidney disease in adults: assessment and management (CG182) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 10 of 60cardiovascular disease (ischaemic heart disease, chronic heart failure, peripheral vascular disease or cerebral vascular disease) structural renal tract disease, recurrent renal calculi or prostatic hypertrophy multisystem diseases

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines